Brimonidine Tartrate 0.2% w/v Eye Drops.

DRUG3 trials

Sponsors

Seagen Inc., AbbVie Deutschland GmbH & Co. KG

Conditions

Recurrent Ovarian Cancer with High Folate Receptor-Alpha ExpressionRecurrent endometrial cancerSecond- or Third-Line Recurrent or Metastatic Cervical Cancerand primary peritoneal cancer (EOC)fallopian tuberecurrent cervical cancerrecurrent epithelial ovarian

Phase 1

A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (anti-FRα antibody-drug conjugate) in Adult Patients with Recurrent Gynaecological Cancers

Active, not recruitingCTIS2023-506842-22-00

AbbVie Deutschland GmbH & Co. KGand primary peritoneal cancer (EOC), fallopian tube, recurrent cervical cancer +2

Start: 2025-05-19Target: 169Updated: 2025-12-22

Phase 2

A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment with Mirvetuximab Soravtansine in Patients with Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression

Active, not recruitingCTIS2023-505617-24-00

AbbVie Deutschland GmbH & Co. KGRecurrent Ovarian Cancer with High Folate Receptor-Alpha Expression

Start: 2024-11-05Target: 46Updated: 2025-12-15

Phase 3

C5721002 _ A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer

CompletedCTIS2023-503813-31-01

Seagen Inc.Second- or Third-Line Recurrent or Metastatic Cervical Cancer

Start: 2021-09-17End: 2025-11-18Target: 188Updated: 2025-11-19